^
Association details:
| Biomarker: | ER Y537S |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | ZN-c5 (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader
Published date:
05/15/2020
Excerpt:
...we evaluated the activity of ZN-c5 in ER mutant models including WHIM20, a Y537S ESR1 patient derived xenograft model. Treatment with ZN-c5 at 40 mg/kg induced 64% tumor growth inhibition while fulvestrant at 200 mg/kg (exposures 8-fold higher than that achieved in the clinic) resulted in 13% tumor growth inhibition.
DOI:
10.1158/1538-7445.AM2020-4373
